Trial of Exenatide for Parkinson's Disease

NCT01971242 on ClinicalTrials.gov · last registry update 2016-11-17

Finished May 2016, after enrolling 60 people. Primary outcome, as filed: Efficacy. exenatide is approved in the US, but not for neurodegenerative — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P2
Drug: exenatide
Bydureon, Byetta
Sponsor: University College, London
Sponsor type: Other
Enrollment: 60
Started: 2014-06
Primary completion: 2016-05 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Efficacy

Conditions studied

Parkinson's Disease

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.